抗体-药物偶联物药物用抗体研究进展

摘要

Antibody drug conjugates(ADC),the new generation of antibody technology,combine the target-specificity of mon-oclonal antibody(mAb)and the highly active cell-killing drugs,taking advantages of the best characteristics out of both components. ADC consist of three different components:antibody,linker and cytotoxic drugs (also frequently referred as payload).The antibody component,the vector to selectively deliver a highly toxic drug to the cancer cell,plays an important role in the development of the ideal ADC.This paper reviews the development and current situations,features,types and target selection of the naked antibody,and the development of different targets antibodies existing at present.%抗体-药物偶联物（antibody-drug conjugates，ADC）由抗体、细胞毒性药物及偶联链三部分组成，兼具了抗体的高特异性和细胞毒素对肿瘤的高毒性，是新一代抗体技术的发展方向之一。作为ADC的载体部分，理想抗体及其靶标的选择是设计开发安全性高、疗效好的ADC药物的重要因素。本文将对ADC药物用抗体的发展现状、特点、类型及靶标选择，以及现有的不同靶点裸抗体的发展进行简要综述，为理想ADC药物的开发提供参考。